ArticleVeterinary research communications2026
In vitro antimicrobial activity of Naja cardiotoxin peptide-3 against clinical isolates from canine otitis.
Article in Veterinary research communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Canine otitis externa is a common multifactorial condition frequently complicated by bacterial and fungal infections. The increasing prevalence of antimicrobial resistance has reduced the effectiveness of conventional therapies, underscoring the need for alternative treatment strategies. Antimicrobial peptides represent a promising option due to their broad-spectrum activity and low propensity to induce resistance. Among these, the Naja Cardiotoxin Peptide-3 (NCP-3), derived from cardiotoxin 1 of the Chinese cobra (Naja atra subsp. atra), has demonstrated potent bactericidal and fungicidal activity with minimal cytotoxicity. In this study, the in vitro antimicrobial activity of NCP-3 was evaluated against clinical isolates obtained from dogs with otitis externa, including multidrug-resistant bacteria and Malassezia pachydermatis. NCP-3 was effective against all reference tested strains except Proteus mirabilis. Among field strains, the highest bactericidal activity was observed on Staphylococcus pseudintermedius (MBC₅₀=3.1 µg/mL; MBC₉₀=6.3 µg/mL), whereas higher concentrations were required to inhibit Pseudomonadaceae (MBC₅₀=12.5 µg/mL). Neither MBC₅₀ nor MBC₉₀ were achieved for Enterobacteriaceae or M. pachydermatis. Time-kill assays demonstrated rapid bactericidal activity of NCP-3 against both reference and clinical Gram-positive strains, with complete inhibition achieved within five minutes. In contrast, Gram-negative reference strains required longer exposure times, with a partial inhibition only at 120 min. Overall, these findings indicate that NCP-3 exhibits stronger antimicrobial activity against Gram-positive bacteria, including resistant strains, than on Gram-negative bacteria and M. pachydermatis field strains. NCP-3 may therefore represent a promising candidate as therapeutic agent for canine otitis externa caused by Gram-positive pathogens, supporting further investigation into its potential applications in veterinary medicine.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.